(Rac)-Modipafant

Research use only, not for human use.

(Rac)-Modipafantis an orally available and selective platelet-activating factor receptor (PAFR) antagonist that inhibits PAF-induced aggregation of washed platelets in rabbits, and can be used to study arthritis and ischemia/reperfusion (I/R) in the superior mesenteric artery (SMA) of the rat.

(Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible platelet activating factor receptor (PAFR) antagonist. (Rac)-Modipafant prevents dengue infection.

——

(Rac)-Modipafant (UK-74505) (10 mg/kg; p.o.; twice a day until day 10) prevents Severe Dengue Infection.(Rac)-Modipafant exhibits highly selective, time-dependent inhibition of PAF-induced aggregation of rabbit washed platelets (IC50=26.3 and 1.12 nM after 0.25 and 60 min preincubation, respectively).(Rac)-Modipafant (5-20 mg/kg; p.o.) dose-dependently inhibits the Zymosan -induced articular hyperalgesia.Animal Model:8- to 10-week-old BALB/c mice (DEN-2 strain infected) Dosage:10 mg/kg Administration:P.o.; twice a day (started on days 0, 3, 5, or 7) until day 10 Result:Decreased by approximately 50% the lethality associated with DEN-2 infection.Animal Model:Male BALB/C (8- to 10- week-old) wild-type mice Dosage:5, 10 and 20 mg/kg Administration:P.o.Result:Dose-dependently inhibited the Zymosan -induced articular hyperalgesia.

——

Others

Other Targets

PAFR

——

——

122956-68-7

605.09

C34H29ClN6O3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (82.63 mM; Ultrasonic )

O=C(OCC)C1=C(NC(=C(C(=O)NC2=NC=CC=C2)C1C=3C=CC=CC3Cl)C)C=4C=CC(=CC4)N5C(=NC=6C=NC=CC65)C

——

(-20℃)

With Ice Pack

≥ 2 years